Aligos Therapeutics Inc (NASDAQ:ALGS)’s traded shares stood at 0.46 million during the last session, with the company’s beta value hitting 2.73. At the close of trading, the stock’s price was $28.67, to imply an increase of 2.50% or $0.7 in intraday trading. The ALGS share’s 52-week high remains $30.00, putting it -4.64% down since that peak but still an impressive 76.42% since price per share fell to its 52-week low of $6.76. The company has a valuation of $102.86M, with an average of 0.42 million shares in intraday trading volume over the past 10 days and average of 303.89K shares over the past 3 months.
Analysts have given a consensus recommendation of Hold for Aligos Therapeutics Inc (ALGS), translating to a mean rating of 1.00. Of 9 analyst(s) looking at the stock, 2 analyst(s) give ALGS a Sell rating. 0 of those analysts rate the stock as Overweight while 4 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -3.67.
Aligos Therapeutics Inc (NASDAQ:ALGS) trade information
After registering a 2.50% upside in the last session, Aligos Therapeutics Inc (ALGS) has traded red over the past five days. The 5-day price performance for the stock is 12.39%, and 206.63% over 30 days. With these gigs, the year-to-date price performance is 72.71%. Short interest in Aligos Therapeutics Inc (NASDAQ:ALGS) saw shorts transact 0.29 million shares and set a 0.73 days time to cover.
The extremes give us $3 and $3 for target low and target high price respectively. As such, ALGS has been trading 89.54% off suggested target high and 89.54% from its likely low.
Aligos Therapeutics Inc (ALGS) estimates and forecasts
Looking at statistics comparing Aligos Therapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. Aligos Therapeutics Inc (ALGS) shares are 112.33% up over the last 6 months, with its year-to-date growth rate higher than industry average at 69.53% against 17.50%. The rating firms project that company’s revenue will shrink -59.91% compared to the previous financial year.
Revenue forecast for the current quarter as set by 3 analysts is 433.33k. Meanwhile, for the current quarter, a total of 3 analyst(s) estimate revenue growth to 333.33k.Earnings reports from the last fiscal year show that sales brought in 2.01M and 986k respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -78.43% before dropping -66.19% in the following quarter.
ALGS Dividends
Aligos Therapeutics Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Aligos Therapeutics Inc (NASDAQ:ALGS)’s Major holders
Aligos Therapeutics Inc insiders hold 17.80% of total outstanding shares, with institutional holders owning 48.86% of the shares at 59.44% float percentage. In total, 48.86% institutions holds shares in the company, led by ARMISTICE CAPITAL, LLC. As of 2024-06-30, the company held over 7.26 million shares (or 4.6471% of shares), all amounting to roughly $2.54 million.
The next major institution holding the largest number of shares is ECOR1 CAPITAL, LLC with 6.39 million shares, or about 4.0919% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $2.24 million.
